Korea United Pharm Inc
Korea United Pharm Inc is a pharmaceutical company that develops, produces, and distributes prescription drugs, primarily in South Korea.
Business. Korea United Pharm Inc (033270.KS) is a South Korean pharmaceutical company engaged in the pharmaceuticals and medical research industry. The firm operates within the Healthcare sector, focusing on product sales as its primary revenue model. It is headquartered in South Korea and is primarily listed on the Korea Exchange (KRX). Specific details regarding operating segments or geographic revenue breakdowns are not available.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Korea United Pharm Inc (033270.KS) is a South Korean pharmaceutical company engaged in the pharmaceuticals and medical research industry. The firm operates within the Healthcare sector, focusing on product sales as its primary revenue model. It is headquartered in South Korea and is primarily listed on the Korea Exchange (KRX). Specific details regarding operating segments or geographic revenue breakdowns are not available.
Korea United Pharm Inc maintains a strong liquidity position, with a current ratio of 5.63 and cash and equivalents of 40,270.45 billion KRW. The company's debt-to-equity ratio is 0.03, indicating a conservative capital structure with minimal leverage. Free cash flow stands at 17,547.74 billion KRW, supporting operational flexibility and potential reinvestment.
Profitability metrics show a return on equity of 8.43% and a return on assets of 7.37%, both exceeding the typical thresholds for the pharmaceutical industry. The company's operating income of 49,480.69 billion KRW and net income of 38,308.01 billion KRW reflect strong earnings performance. Gross profit of 160,595.07 billion KRW indicates efficient cost management.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond South Korea. This concentration may expose the company to regional economic and regulatory risks.
Looking ahead, Korea United Pharm Inc is projected to maintain stable revenue growth, supported by its strong cash flow and low debt levels. Analysts have assigned a mean price target of 30,000 KRW, with a mean recommendation of 1.50, indicating a generally positive outlook.
Risk factors for the company include potential regulatory changes in the pharmaceutical sector and the high cost of R&D for new drug approvals. The company has no immediate filing-based liquidity or dilution flags, and dilution risk is assessed as low.
Recent filings and transcripts indicate no major corporate events or strategic shifts in the past quarter. The company continues to focus on its core pharmaceutical business and has not disclosed any material new ventures or partnerships.
- Korea United Pharm Inc has a strong liquidity position with a current ratio of 5.63 and significant cash reserves.
- The company's profitability metrics, including ROE of 8.43% and ROA of 7.37%, are robust and above industry norms.
- Revenue is concentrated in a single business segment and geographic region, increasing exposure to local market risks.
- Analysts project a stable outlook with a mean price target of 30,000 KRW and a mean recommendation of 1.50.
- The company faces low liquidity and dilution risks, with no immediate filing-based flags.
- Regulatory and R&D risks remain key concerns for the company's long-term performance.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 3 021,00 |
| Revenue | —no estimate | —no estimate | 303,5B KRW |
| Operating income | —no estimate | —no estimate | 55,9B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Korea United Pharm Inc Market data — financials · 2026-05-26
- Korea United Pharm Inc Market data — analyst estimates · 2026-05-26